There are still challenges with delivering vaccines to the children who need them the most. For example, figures show that 60% of eligible children in those settings are not actually getting vaccinated. That translates to 80.7 million children not getting vaccines at the time they should get them.
There is more work to be done in implementation of vaccination programmes in those communities and we’re dedicated to the challenge. Because no matter how good a vaccine is, it can’t help prevent pneumonia unless it is used. We have to get vaccines to the children who need them. We need to translate vaccines to vaccination. That is what I have the opportunity to contribute to at GSK.”
Our employees like Richard are working hard to tackle the challenge of pneumonia vaccination in developing countries. But we cannot do it alone. GSK works with a number of partners to deliver vaccines to the children who need them the most.
Our commitment to Gavi
Over the past 16 years, Gavi has played a valuable role in bringing new and under-used vaccines to hundreds of millions of children in the world’s poorest countries. GSK is one of the largest contributors of vaccines to Gavi, supplying innovative vaccines for rotavirus, pneumococcal disease and cervical cancer, at significantly reduced prices to help accelerate access in developing countries.
Supporting vulnerable refugee communities
The current refugee crisis affecting areas such as Syria and South Sudan can leave displaced people unable to access healthcare, and potentially vulnerable to vaccine-preventable disease. In response to this growing problem, we have committed to supply our essential vaccines to internationally recognised civil society organisations (CSOs) – such as Médecins Sans Frontières – at our lowest prices for use in acute humanitarian situations where governments are unable to respond. Our pneumonia vaccine is the first vaccine we will supply in this way.